CAR-T treatments involve extracting and genetically modifying T cells within a patient’s immune system to better identify and attack cancerous cells.
“Our latest research program with Peter Mac is an important part of our development plans, which include institutional and commercial laboratories,” he said.
“AML remains a very difficult disease to treat, especially in the relapsed and refractory setting, with patients often too sick to endure vigorous treatment,” he said.
31st May 2024
8th May 2024
4th May 2024
Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG)
including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.
Please click here to read our full warning.